More Biotech Firms Going Public Through Blank-Check IPOs

Loeb & Loeb vice chair and co-chair of the firm's Capital Markets and Corporate Practice Mitch Nussbaum speaks on the rise of biotechnology special purpose acquisition companies (SPACs) and their correlation with blank check initial public offerings.

Click here to read the full article on the Law360 website.